| |
|
|
|
|
|
Breast cancer is the most common life-threatening malignant lesion
in women of many developed countries today, with approximately
180,000 new cases diagnosed every year. Roughly half of these
newly diagnosed patients are node-negative, however 30 of these
cases progress to metastatic disease.
There are a number of tumor markers that can help clinicians to
identify and diagnose which breast cancer patients will have
aggressive disease and which will have an indolent course. These
markers include estrogen and progesterone receptors, DNA ploidy
and percent-S phase profile, epidermal growth factor
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
Breast cancer is the most common life-threatening malignant lesion in women of many developed countries today, with approximately 180,000 new cases diagnosed every year. Roughly half of these newly diagnosed patients are nodenegative, however 30 of these cases progress to metastatic disease. There are a number of tumor markers that can help clinicians to identify and diagnose which breast cancer patients will have aggressive disease and which will have an indolent course. These markers include estrogen and progesterone receptors, DNA ploidy and percent-S phase profile, epidermal growth factor
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The CA 15-3 antigen is a high-molecular-weight mucin glycoprotein termed MUC-1. It has been characterized with
monoclonal antibodies developed against purified extracts of a membrane fraction isolated from a human breast
carcinoma (clone DF3) and against human milk fat globule membrane (clone 115D8).
Other names for the mucin include polymorphic epithelial mucin (PEM), epithelial membrane antigen (MEA) or episalin.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
Biomarker for early detection of breast cancer recurrence: Supported by over 2,000 peer-reviewed publications, CA 15-3® is indicated for the quantitative determination of DF3 antibody-defined antigen, encoded by the MUC 1 gene, in serum and plasma of patients previously treated for stage II or stage III breast cancer.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA),
such as CA19-9 and CA19-5, has come to be recognized as
circulating cancer associated antigens for gastrointestinal cancer.
CA19-9 represents the most important and basic carbohydrate
tumor marker. The immunohistologic distribution of CA19-9 in
tissues is consistent with the quantitative determination of higher
CA19-9 concentrations in cancer than in normal or inflamed tissues.
Recently reports indicates that the serum CA19-9 level is frequently
elevated in the serum of subjects with various gastrointestinal
malignancies, such a
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues. Recently reports indicates that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The CA 19-9 RIA, an in vitro diagnostic test for the quantitative measurement of the CA 19-9 tumor associated antigen,
in human serum or plasma, is indicated for the serial measurement of CA 19-9 to aid in the management of patients
diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in:
Monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of serum or plasma CA
19-9 above the cutoff, at the time of diagnosis.
CA 19-9 values must be interpreted in conjunction with all other available clinical and laboratory data before a med
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
Biomarker for pancreatic cancer: CA 19-9™ sets the standard of excellence as an assay for the serial measurement of CA 19-9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The CA 72-4™ RIA is an in vitro test for the quantitative measurement of TAG 72 in human serum and plasma.
Initial research indicates that determination of circulating TAG 72 levels by the CA 72-4™ RIA could aid in the
management of patients with diagnosed gastric cancer and other gastrointestinal (GI) malignancies.
Radioimmunoassay for the detection of Tumor-Associated Glycoprotein 72 (TAG 72) in serum or plasma. This
radioactive material may be received, acquired, possessed, and used only by physicians, clinical laboratories, or
hospitals and only for in vitro clinical or laboratory testes n
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The CA15-3 EIA test is intended for use as a monitoring and screening
test for breast cancer. An abnormal result (i.e., elevated serum CA15-3
level) indicates further clinical management. CA15-3 is a useful tumor
marker for patients in clinical remission following treatment. Postoperative
serum CA15-3 values which fail to return to normal, strongly
suggest the presence of residual tumor, while tumor recurrence is often
accompanied by a rise of serum CA15-3 before progressive disease is
clinically evident.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|